JPRN-UMIN000007854招募中2 期
Phase 2 study of Bevacizumab Beyond Progression treatment in patients with advanced non-squamous non-small-cell Lung cancer - BBPL study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)symptoms due to brain metastasis (2)hemoptysis (3)significant hemosputum (4)radiation therapy to chest region (5)significant infectious disease (6)severe conplication (7)uncontrollable acsites, plueral effusion, cardiac effusion (8)active multiple cancer (9)severe drug allergy (10)unnable to administer vitamin B12.reject to Vitamin B12 (11)interstitial pneumoniae or pulmonary fibrosis (12)uncontrollable hypertension (13)uncontrollable gastrointestinal tract ulcer (14)perforation of the digestive tract or experimental operation (15)doctors estimated innadequated
研究者
相似试验
招募中
2 期
Phase 2 study of bevacizumab in a fixed term for glioblastomaglioblastomaJPRN-UMIN000026856Fujita Health University10
进行中（未招募）
不适用
A phase II trial assessing bevacizumab in the treatment of advanced or metastatic angiosarcomapatients with advanced or metastatic angiosarcomaEUCTR2004-004546-41-FIHelsinki University Central Hospital10
已完成
2 期
A Phase II Study of Bevacizumab (Avastin®) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapyon-sq NSCLC with previously treatedJPRN-UMIN000007123Hiroshima University Hospital Respiratory medicine34
进行中（未招募）
不适用
Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88
进行中（未招募）
1 期
Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado HER-2 negativo - AvaluzEUCTR2008-003657-32-ESRoche Farma S.A.85